JP2025504916A5 - - Google Patents

Info

Publication number
JP2025504916A5
JP2025504916A5 JP2024544446A JP2024544446A JP2025504916A5 JP 2025504916 A5 JP2025504916 A5 JP 2025504916A5 JP 2024544446 A JP2024544446 A JP 2024544446A JP 2024544446 A JP2024544446 A JP 2024544446A JP 2025504916 A5 JP2025504916 A5 JP 2025504916A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
group
compound according
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024544446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504916A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/011659 external-priority patent/WO2023146990A1/en
Publication of JP2025504916A publication Critical patent/JP2025504916A/ja
Publication of JP2025504916A5 publication Critical patent/JP2025504916A5/ja
Pending legal-status Critical Current

Links

JP2024544446A 2022-01-26 2023-01-26 化合物及び使用方法 Pending JP2025504916A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263303368P 2022-01-26 2022-01-26
US63/303,368 2022-01-26
US202263435212P 2022-12-23 2022-12-23
US63/435,212 2022-12-23
PCT/US2023/011659 WO2023146990A1 (en) 2022-01-26 2023-01-26 Compounds and methods of use

Publications (2)

Publication Number Publication Date
JP2025504916A JP2025504916A (ja) 2025-02-19
JP2025504916A5 true JP2025504916A5 (cg-RX-API-DMAC7.html) 2026-02-16

Family

ID=85383019

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024544446A Pending JP2025504916A (ja) 2022-01-26 2023-01-26 化合物及び使用方法

Country Status (5)

Country Link
US (1) US20250163048A1 (cg-RX-API-DMAC7.html)
EP (1) EP4469455A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025504916A (cg-RX-API-DMAC7.html)
TW (1) TW202339737A (cg-RX-API-DMAC7.html)
WO (1) WO2023146990A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024037607A1 (zh) * 2022-08-19 2024-02-22 北京望实智慧科技有限公司 Prmt5抑制剂
CN118359607A (zh) * 2023-01-17 2024-07-19 苏州浦合医药科技有限公司 Prmt5-mta抑制剂
WO2024160058A1 (zh) * 2023-01-31 2024-08-08 四川科伦博泰生物医药股份有限公司 草酸二酰胺化合物、包含其的药物组合物及其制备方法和用途
WO2025217297A1 (en) 2024-04-09 2025-10-16 Tango Therapeutics, Inc. Prmt5 inhibitors for use in methods of treating mta-accumulating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
WO2011079236A1 (en) 2009-12-22 2011-06-30 The Ohio State University Research Foundation Compositions and methods for cancer detection and treatment
WO2021004547A1 (en) * 2019-07-11 2021-01-14 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as inhibitors of hpk1
CN116568677B (zh) * 2020-07-31 2026-07-28 探戈医药股份有限公司 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物
EP4469447A1 (en) * 2022-01-26 2024-12-04 Tango Therapeutics, Inc. Compounds and methods of use

Similar Documents

Publication Publication Date Title
JP6581320B2 (ja) 腫瘍治療用医薬組成物
RU2650895C2 (ru) Соединения замещенных пиразолонов и способы использования
CA3208313A1 (en) Isoindolinone compounds
JP2026009899A (ja) NaV1.8を阻害するピリジンカルボキサミド化合物
JP2010539110A5 (cg-RX-API-DMAC7.html)
WO2018057973A4 (en) Compounds and methods for ido and tdo modulation, and indications therefor
JP2010265302A5 (cg-RX-API-DMAC7.html)
MX2013002431A (es) Nuevos compuestos y composiciones para la inhibicion de nampt.
RU2013154117A (ru) Производные 1-фенил-2-пиридинилалкильных спиртов в качестве ингибиторов фосфодиэстеразы
IL298592A (en) Combination therapy for treatment of cancer
WO2022219412A1 (en) Isoindolinone amide compounds useful to treat diseases associated with gspt1
JP2014518544A5 (cg-RX-API-DMAC7.html)
JP2017530185A5 (cg-RX-API-DMAC7.html)
RU2017111200A (ru) Циклогексилэтилзамещенные диаза- и триаза-трициклические соединения в качестве антагонистов индоламин-2,3-диоксигеназы для лечения рака
JP2018501315A5 (cg-RX-API-DMAC7.html)
CN109790166A (zh) 咪唑并吡啶化合物用于治疗癌症
JP2010528021A5 (cg-RX-API-DMAC7.html)
JP6695353B2 (ja) Fgfr4阻害剤としてのホルミル化n−複素環式誘導体
JP2018500342A (ja) トリアゾロピリミジン化合物およびその使用
HRP20201469T1 (hr) Derivati tetrahidroizokinolina
JP2009513703A5 (cg-RX-API-DMAC7.html)
JP2017537948A5 (cg-RX-API-DMAC7.html)
TW202317532A (zh) Aak1抑制劑及其用途
RU2013144571A (ru) Алинзамещенные хиназолины и способы их применения
JP2017537111A (ja) ヘテロ環式誘導体およびその使用